New hope for hard-to-treat blood cancers: experimental drug imetelstat tested in phase 2 trial

NCT ID NCT05583552

Ongoing Disease control Sponsor: GCP-Service International West GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes or acute myeloid leukemia that did not improve after standard therapy. The goal is to see if the drug can improve blood cell counts and control the disease. Participants who respond can continue treatment until the disease worsens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

CHU Nantes - Hôtel Dieu

Nantes, France
CHU de Toulouse

Toulouse, France
Hôpital Archet 1

Nice, France
Hôpital Saint-Louis

Paris, France
Klinikum rechts der Isar

München, Germany
Linear Clinical Research

Nedlands, Australia
Marien Hospital Düsseldorf

Düsseldorf, Germany
Royal Adelaide Hospital

Adelaide, Australia
Royal Brisbane and Women's Hospitals

Brisbane, Australia
Universität Jena, Medizinische Fakultät

Jena, Germany
Universität Leipzig, Medizinische Fakultät

Leipzig, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.